Dr. Mapp joined Cooper University Health Care in 2023. She provides operational oversight for the Women’s and Children’s Institute, including Obstetrics and Gynecology, Pediatrics, Child Life, Neonatal and Pediatric Critical Care, Cleft Palate Clinic, and the Safe Kids Outreach Program as well as Respiratory, Pulmonary Function Testing, and Interventional Pulmonary.
Ms. Gruber joined Cooper in 1989 and has advanced from a staff nurse to her current position of Assistant Vice President, Nursing Operations. She provides operational oversight for Emergency Services, Urgent Care Centers, Inpatient Psychiatry, Cooper Transfer Center, Supplemental Staffing, and Logistics.
Ms. Campbell is the Chief Advanced Practice Provider. Her administrative responsibilities include oversight and standardization of recruitment/retention, professional development and engagement, quality and safety, education and research activities for Advanced Practice Providers (APPs) and Licensed Independent Practitioners (LIPs). This broad oversight includes Nurse Practitioners, Physician Assistants, CRNAs and Psychologists. Ms.
Ms. Floyd started her nursing career in 1981 graduating with a diploma in nursing and immediately transitioned into critical care. Years at the bedside and desire to grow both in skill and knowledge resulted in further pursuit of career goals including a BSN and later a Master of Science in Nursing with an Emphasis in Nursing Education (MSN-Ed) degree.
Dr. Devine is responsible for professional nursing practice across the continuum of care to ensure safety, service, and quality outcomes for Cooper University Health Care's diverse patient population. In addition, she has administrative and operational leadership responsibility for Nursing and Patient Care Services. As SVP/CNE, Dr. Devine continues to advance nursing practice by engaging nurses in re-defining a professional practice model and shared governance structure that are grounded in theoretical tenets which align to organizational mission, vision, and values.
Short Title: Exceptional Responders
This clinical trial studies eliminating surgery and how well radiation therapy after systemic therapy works in treating patients with HER2 positive or triple negative breast cancer when image-guided biopsy shows no residual cancer. Patients then receive standard breast radiotherapy.
Study Number:
2016-0046
Study Status:
Enrolling
Treatment Agent:
Radiation, Surgery
National Clinical Trial Identified Number: NCT02945579
Disease:
Study Phase:
Not applicable
researchcancer@cooperhealth.edu
Multicenter trial for eliminating breast cancer surgery or radiotherapy in exceptional responders to neoadjuvant systemic therapy
Hide from Search:
Off
Physician Name:
Short Title: BR009/OFSET
To determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Study Number:
BR009
Study Status:
Enrolling
Treatment Agent:
Ovarian Function Suppression, Aromatase Inhibitor, Adjuvant Chemotherapy, Ovarian Function Suppression
National Clinical Trial Identified Number: NCT05879926
Disease:
Study Phase:
III
ResearchCancer@CooperHealth.edu
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25
Hide from Search:
Off
Physician Name:
Department:
Short Title: LU008
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to standard treatment (image guided radiation therapy [IGRT] and chemotherapy followed by immunotherapy with durvalumab) versus standard treatment alone in treating patients with non-small cell lung cancer that cannot be treated by surgery (inoperable). SBRT uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. IGRT is a type of radiation that uses a computer to create picture of the tumor, to help guide the radiation beam during therapy, making it more accurate and causing less damage to healthy tissue.
Study Number:
LU008
Study Status:
Enrolling
Treatment Agent:
Cisplatin, Carboplatin, Paclitaxel, Pemetrexed, and Etoposide
National Clinical Trial Identified Number: NCT05624996
Disease:
Study Phase:
III
ResearchCancer@CooperHealth.edu
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for LocallyAdvanced Non-Small Cell Lung Canc
Hide from Search:
Off
Physician Name:
Department:
Short Title: GY026
This phase II/III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma.
Study Number:
GY026
Study Status:
Enrolling
Treatment Agent:
Carboplatin, Hyaluronidase-zzxf/Pertuzumab/Trastuzumab, Paclitaxel, Trastuzumab/Hyaluronidase-oysk
National Clinical Trial Identified Number: NCT05256225
Disease:
Study Phase:
II/III
Researchcancer@cooperhealth.edu
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined with Either Trastuzumab and Hyaluronidase-Oysk (Herceptin Hylecta) or Pertuzumab, Trastuzumab, and Hyaluronidase-Zzxf (Phesgo) in Her2 Positive, Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
Hide from Search:
Off
Physician Name:
Department:
Short Title: SURVENT
The trial’s primary aim is to determine if patients undergoing endoscopic eradication therapy will demonstrate less neoplastic progression and a lower incidence of esophageal adenocarcinoma compared to patients undergoing surveillance.
Study Number:
SURVENT
Study Status:
Enrolled
Treatment Agent:
Not Applicable
National Clinical Trial Identified Number: NCT05753748
Disease:
Study Phase:
Not Applicable
researchcancer@cooperhealth.edu
A Multicenter Randomized Controlled Trial of Surveillance vs. Endoscopic Therapy for Barrett’s Esophagus with Low-grade Dysplasia
Index Extra:
Esophageal, head and neck, Dysplasia, Barrett’s, Esophagus, gastro
Hide from Search:
Off
Physician Name:
Department:
